Bapineuzumab

Bapineuzumab is a humanized monoclonal antibody which acts on the nervous system and has potential therapeutic value for the treatment of Alzheimer's disease and quite possibly Glaucoma [1]. Bapineuzumab is an antibody to the beta-amyloid (Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. Previous clinical trials for the first iteration of the drug, called AN-1792, patients with Alzheimer's disease using active immunization had positive outcomes with removal of plaques and quality of life increases, but 6% of subjects developed aseptic meningitis and the trial was stopped last decade(for a review, see Woodhouse et al. 2007 [2]). Bapineuzumab is currently being co-developed by the pharmaceutical companies Élan and Wyeth and has just entered Phase III trials.